Now that multiple biosimilars of adalimumab (Humira) are approved, though none have launched in the United States or European Union, attention is turning toward the next wave of biosimilar candidates.
Now that multiple biosimilars of adalimumab (Humira) are approved, though none have launched in the United States or European Union, attention is turning toward the next wave of biosimilar candidates.
Click to read more about the biosimilar pipeline.
Writing in Current Rheumatology Reports, Sizheng Zhao, MBChB, of Aintree University Hospital in Liverpool, United Kingdom, and colleagues report that, in addition to Amgen’s Amjevita/Amgevita, Boehringer Ingelheim’s Cyltezo, and Samsung Bioepis’ Imraldi, an additional 10 adalimumab biosimilars are in phase 3 development:
On a global level, 3 more adalimumab biosimilars have been approved in other regulatory territories: CinnoRA (approved in Iran), Exemptia, and Adfar (both approved in India).
“The year 2018 will see several biosimilars of adalimumab emerge in clinical practices worldwide,” write the authors, adding that “These adalimumab biosimilars, and many more in the pipeline, will offer exciting opportunities in improving treatment access and increasing treatment options worldwide.”
Reference
Zhao S, Chadwick L, Mysler E, Moots RJ. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(10):57. doi: 10.1007/s11926-018-0769-6.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.